SEPN Stock Summary and Trading Ideas (Septerna | NASDAQ:SEPN)

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna trades on the NASDAQ stock market under the symbol SEPN.

As of September 4, 2026, SEPN stock price declined to $36.75 with 183,669 million shares trading.

SEPN has a beta of 0.71, meaning it tends to be less sensitive to market movements. SEPN has a correlation of 0.02 to the broad based SPY ETF.

SEPN has a market cap of $1.72 billion. This is considered a Small Cap stock.

Last quarter Septerna reported $27 million in Revenue and -$.29 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.20.

The top ETF exchange traded funds that SEPN belongs to (by Net Assets): VTI, VXF, XPH, IWO, VTWO.

SEPN has outperformed the market in the last year with a return of +160.3%, while the SPY ETF gained +19.8%. In the last 3 month period, SEPN beat the market returning +17.2%, while SPY returned +2.0%. However, in the most recent 2 weeks SEPN has underperformed the stock market by returning -8.1%, while SPY returned +0.6%.

SEPN support price is $35.34 and resistance is $38.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SEPN shares will trade within this expected range on the day.